Compare Inovio Pharmaceuticals Inc (INO) vs Mongodb Inc (MDB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Mongodb Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Mongodb Inc trades at $326.28 (market cap $26.01B). The key difference: Mongodb Inc is far larger — about 291.4× Inovio Pharmaceuticals Inc's market cap, and Mongodb Inc is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | MDB | |
|---|---|---|
Market Cap | $89.27M | $26.01B |
Sector | Health | Technology |
52-Week High | $2.87 | $440.25 |
52-Week Low | $1.05 | $201.08 |
Enterprise Value | $60.28M | $23.61B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
MongoDB (MDB) trades at $324.44, up 3.88% today, with strong analyst support (82% buy ratings) and a $400.39 consensus price target. The stock shows bearish technical signals but has consistently beaten earnings expectations, with Q1 2026 EPS of $1.32 surpassing the $1.19 estimate. Revenue growth remains robust at $2.01B for 2025, though profitability challenges persist with a negative net margin of -1.12%.
MDB presents a growth investment opportunity with accelerating revenue and improving margins, but faces execution risks and competitive pressures. The stock's premium valuation (P/S 9.77) requires sustained high growth, while negative cash flow and ongoing profitability concerns warrant caution despite Wall Street optimism.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Mongodb Inc
Founded in 2007, MongoDB is a document-oriented database with nearly 33,000 paying customers and well past 1.5 million free users. MongoDB provides both licenses as well as subscriptions as a service for its NoSQL database. MongoDB's database is compatible with all major programming languages and is capable of being deployed for a variety of use cases.
Read more on MDB →
